On August 19, pharmaceutical giant Merck and biotechnology company Moderna announced a significant breakthrough in the treatment of melanoma. Their joint development—a personalized mRNA vaccine called intismeran autogene (also known as V940 or mRNA-4157)—achieved its primary endpoints in the third phase of clinical trials. The drug was used in combination with the anti-tumor agent Keytruda.
Key results of the INTerpath-001 study
The large-scale INTerpath-001 study involved 1,137 patients with stage IIB-IV melanoma whose tumors had been completely surgically removed. Participants were divided into two groups: one received the vaccine combined with Keytruda, the other received only Keytruda. The results showed statistically significant improvements in both recurrence-free survival and the absence of distant metastases.
This is the first positive phase three result in history for personalized neoantigen therapy and the mRNA approach in cancer treatment. Although specific efficacy figures have not yet been disclosed and will be presented at international medical conferences, the companies confirmed that no new safety risks were identified. The study will continue to assess overall survival.
Recall that in the second phase of trials, the combination had already shown impressive results: over five years of follow-up, the risk of recurrence or death dropped by 49%, and the likelihood of distant metastases by 59%.
The role of artificial intelligence in vaccine development
The uniqueness of intismeran autogene lies in its individuality. Unlike standard vaccines, this drug is created personally for each patient. The process begins with sequencing tumor and blood samples. Moderna's algorithms then analyze mutations and select up to 34 neoantigens—potential targets for the immune system. Based on this data, an individualized mRNA vaccine is produced, which trains the immune system to recognize and attack cancer cells.
Moderna actively uses built-in AI tools to predict the most effective neoantigens and optimize production processes. Given that each batch is unique, algorithms help plan the output of thousands of individualized drugs. Keytruda, in turn, works differently—it blocks the mechanism that suppresses the immune response, allowing the vaccine to work more effectively.
Market reaction and prospects
The news triggered a real surge in the stock market. Moderna's shares soared by 131%, reaching $163—a record one-day gain in the company's history. However, by the time of writing this analysis, quotes had corrected by nearly 15%. The sharp jump led to losses for short sellers of approximately $4.8 billion, given that about 13.5% of shares were in short positions.
Merck and Moderna plan to present the results to regulators and discuss filing a registration application. The therapy remains experimental for now. The companies are also exploring the vaccine's use in other types of cancer—lung, bladder, and kidney. This opens a new era in oncology, where AI plays a key role in creating highly personalized treatments.
My analysis: The success of this therapy could be a turning point for the entire industry. If the results are confirmed in practice, we will witness a fundamental shift from universal protocols to individualized medicine, where algorithms will act as the chief architect of treatment. Investors should closely monitor the development of this direction—the growth potential is enormous, but volatility will also be high.